Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose cytosine arabinoside: pharmacological and clinical aspects.

Literature DB >> 3276364

High-dose cytosine arabinoside: pharmacological and clinical aspects.

W G Peters¹, L P Colly, R Willemze.

Abstract

Entities: Chemical

Mesh：

Substances：
Cytarabine

Year: 1988 PMID： 3276364 DOI： 10.1007/bf00321053

Source DB: PubMed Journal: Blut ISSN： 0006-5242

× No keyword cloud information.

78 in total

1. Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase.

Authors: R L Momparler
Journal: Mol Pharmacol Date: 1972-05 Impact factor: 4.436

2. In vivo effects of cytosine arabinoside on deoxyribonucleic acid replication in Chinese hamster ovary cells. 1. Resolution of differential effects on mitochondrial and nuclear deoxyribonucleic acid synthesis.

Authors: N H Heintz; J L Hamlin
Journal: Biochemistry Date: 1983-07-19 Impact factor: 3.162

3. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.

Authors: R Willemze; W E Fibbe; F E Zwaan
Journal: Neth J Med Date: 1983 Impact factor: 1.422

4. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.

Authors: C W Wan; T W Mak
Journal: Cancer Res Date: 1978-09 Impact factor: 12.701

5. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.

Authors: P A Cassileth; C B Begg; R Silber; A Spiers; P T Burkart; W Scharfman; W H Knospe; J M Bennett; J J Mazza; M M Oken
Journal: Cancer Treat Rep Date: 1987-02

6. High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma.

Authors: D J Adelstein; H M Lazarus; J D Hines; R H Herzig
Journal: Cancer Date: 1985-10-01 Impact factor: 6.860

7. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.

Authors: P P Major; E M Egan; G P Beardsley; M D Minden; D W Kufe
Journal: Proc Natl Acad Sci U S A Date: 1981-05 Impact factor: 11.205

8. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.

Authors: H M Haupt; G M Hutchins; G W Moore
Journal: Am J Med Date: 1981-02 Impact factor: 4.965

9. Metabolism of ara-C by blast cells from patients with ANLL.

Authors: D D Ross; B W Thompson; C C Joneckis; S A Akman; C A Schiffer
Journal: Blood Date: 1986-07 Impact factor: 22.113

10. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine.

Authors: J H Lass; H M Lazarus; M D Reed; R H Herzig
Journal: Am J Ophthalmol Date: 1982-11 Impact factor: 5.258

10 in total

1. Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia.

Authors: R Willemze; W E Fibbe; J C Kluin-Nelemans; J H Falkenburg; D J Richel; W G Peters; G J den Ottolander; A Brand; F E Zwaan
Journal: Ann Hematol Date: 1991 Feb-Mar Impact factor: 3.673

Review 2. Acute myelogenous leukaemia in children.

Authors: S O Lie
Journal: Eur J Pediatr Date: 1989-02 Impact factor: 3.183

3. Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine.

Authors: L T Vlasveld; F E Zwaan; W E Fibbe; R T Tjon; T A Tham; P M Kluin; R Willemze
Journal: Ann Hematol Date: 1991-04 Impact factor: 3.673

Review 7. The toxicity of cytarabine.

Authors: J Stentoft
Journal: Drug Saf Date: 1990 Jan-Feb Impact factor: 5.606